What is Cytomos?
Cytomos specializes in advanced cell analysis technology, leveraging its proprietary AuraCyt® and Celledonia systems to overcome traditional bioprocessing bottlenecks. Their innovative solutions provide rapid, data-rich insights crucial for cell line development and bioprocess optimization. The company serves clients in sectors such as monoclonal antibodies, viral vector production, and cell therapies, aiming to enhance bioprocessing efficiency and reduce time-to-market through streamlined development and cost reduction.
How much funding has Cytomos raised?
Cytomos has raised a total of $13.3M across 3 funding rounds:
Angel/Seed
$1.9M
Other Financing Round
$5M
Other Financing Round
$6.3M
Angel/Seed (2022): $2M with participation from Old College Capital and Scottish Enterprise
Other Financing Round (2023): $5M led by British Business Bank, Scottish Enterprise, Archangels, and Old College Capital
Other Financing Round (2024): $6.4M supported by Scottish Enterprise, British Business Bank, Archangel Capital Partners, and Edinburgh Innovations
Key Investors in Cytomos
Scottish Enterprise
Scottish Enterprise is a national economic development agency of the Scottish Government, focused on driving economic growth and innovation within Scotland.
British Business Bank
The British Business Bank is a government-owned bank dedicated to increasing the supply of credit to small and medium enterprises and providing business advice services.
Archangels
Archangels is an investment group focused on supporting early-stage businesses, particularly those with strong growth potential and innovative technologies.
What's next for Cytomos?
The recent major strategic investment signals a pivotal phase for Cytomos, likely enabling expansion of its technological capabilities and market reach. This capital will probably fuel further research and development into its cell analysis platforms, potentially leading to new product iterations or enhanced features. The company's focus on bioprocessing optimization positions it to capitalize on the growing demand for efficient and cost-effective solutions in the biopharmaceutical industry, suggesting a strategic push towards scaling operations and solidifying its market leadership.
See full Cytomos company page
